Loading...
Market
Primary Reason for Outcome of Halozyme's Acquisition Attempt by End of 2025?
2
Resolution / Starting Odds
Regulatory approval • 25%
Shareholder approval • 25%
Financial considerations • 25%
Strategic realignment • 25%
Official statements from Halozyme, Evotec, or regulatory bodies
Story
Halozyme Proposes €2 Billion Takeover of Evotec at €11 Per Share, 27% Premium
Nov 14, 2024, 09:30 PM
Halozyme Therapeutics is reportedly exploring a takeover of the German drugmaker Evotec, with a proposed acquisition valued at approximately €2 billion ($2.1 billion). The offer includes a cash payment of €11 per share, representing a 27% premium over Evotec's last closing price. This potential acquisition aims to enhance Halozyme's drug discovery and development portfolio. The interest from Halozyme comes as Evotec has garnered attention in the biotechnology sector, with various reports confirming the ongoing discussions between the two companies.
View original story
Similar markets
Biotech Company • 25%
Pharmaceutical Company • 25%
Medical Device Company • 25%
No major acquisition • 25%
Significant progress • 25%
Moderate progress • 25%
Little progress • 25%
No progress • 25%
Pfizer • 25%
AstraZeneca • 25%
GlaxoSmithKline • 25%
Other • 25%
Positive response • 25%
Neutral response • 25%
Negative response • 25%
Mixed response • 25%
Successful market introduction • 25%
Delayed market introduction • 25%
Project discontinued • 25%
Acquisition divested • 25%
New Phase 3 trial initiated • 25%
Govorestat approval without new trial • 25%
Govorestat development halted • 25%
Partnership or acquisition for Govorestat • 25%
New clinical trial for different vaccine • 25%
Partnership with another biotech company • 25%
Company restructuring or layoffs • 25%
Other • 25%
Regulatory challenges • 25%
Trust's decision • 25%
Financial constraints • 25%
Strategic realignment • 25%